BiotechTube

Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous Placebo

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sedation

Conditions

Sedation

Trial Timeline

Jul 26, 2017 → Jul 1, 2018

NCT ID
NCT03293277

About Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous Placebo

Intranasal Dexmedetomidine + Intravenous Dexmedetomidine + Intranasal Placebo + Intravenous Placebo is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Sedation. The current trial status is unknown. This product is registered under clinical trial identifier NCT03293277. Target conditions include Sedation.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03293277Phase 1UNKNOWN

Competing Products

20 competing products in Sedation

See all competitors
ProductCompanyStageHype Score
AQUAVAN® (fospropofol disodium) Injection + Midazolam HCIEisaiPhase 3
77
Fospropofol disodium + Fospropofol disodium + Placebo + Midazolam + FentanylEisaiApproved
85
fospropofol disodium Subgroup 1 Lower Dose + fospropofol disodium Subgroup 1 Approved Dose + fospropofol disodium Subgroup 2 Lower Dose + fospropofol disodium Subgroup 2 Approved Dose + fospropofol disodium Subgroup 3 Lower Dose + fospropofol disodium Subgroup 3 Approved DoseEisaiApproved
85
AQUAVAN® (fospropofol disodium) InjectionEisaiPhase 2/3
65
AQUAVAN (fospropofol disodium; GPI 15715 )EisaiPhase 2
52
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)Johnson & JohnsonPhase 3
77
Remimazolam TosilateJiangsu Hengrui MedicineApproved
85
Remimazolam TosilateJiangsu Hengrui MedicinePhase 1/2
41
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
23
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
77
Remimazolam Tosilate + Propofol Medium and Long Chain Fat Emulsion InjectionJiangsu Hengrui MedicinePhase 3
77
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 3
77
SHR0302 Base Gel + SHR0302 Base Gel PlaceboJiangsu Hengrui MedicinePhase 1
33
Remimazolam Tosilate for InjectionJiangsu Hengrui MedicinePre-clinical
23
Remimazolam Tosilate for Injection + Remimazolam Tosilate for InjectionJiangsu Hengrui MedicineApproved
85
Remimazolam Tosilate for injection + Propofol InjectionJiangsu Hengrui MedicinePhase 2/3
65
Dexmedetomidine hydrochloride nasal spray + Dexmedetomidine hydrochloride nasal spray blank preparation.Jiangsu Hengrui MedicinePhase 1
33
Remimazolam Tosilate + PropofolJiangsu Hengrui MedicinePhase 2
52
dexmedetomidine nasal spray + dexmedetomidine hydrochloride nasal spray blank preparationJiangsu Hengrui MedicinePhase 2/3
65
Remimazolam Tosilate + Propofol Injection.Jiangsu Hengrui MedicinePhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85